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Abstract
The heart’s extraordinary metabolic flexibility allows it to adapt to normal changes in physiology 
in order to preserve its function. Alterations in the metabolic profile of the heart have also been 
attributed to pathological conditions such as ischemia and hypertrophy; however, research during 
the past decade has established that cardiac metabolic adaptations can precede the onset of 
pathologies. It is therefore critical to understand how changes in cardiac substrate availability and 
use trigger events that ultimately result in heart dysfunction. This review examines the 
mechanisms by which the heart obtains fuels from the circulation or from mobilization of 
intracellular stores. We next describe experimental models that exhibit either an increase in 
glucose use or a decrease in FA oxidation, and how these aberrant conditions affect cardiac 
metabolism and function. Finally, we highlight the importance of alternative, and relatively under 
investigated, strategies for the treatment of heart failure.
Introduction
The heart, the powerhouse of the body and the organ with the greatest energy requirement, is 
remarkably flexible when it comes to substrate use; it is this metabolic flexibility that 
confers the heart’s remarkable resiliency. The adult heart has the ability to switch energy 
sources as dictated by substrate availability, hormonal status, and physiological conditions 
[1, 2]. Sixty to 90% of the energy used by the adult fasting heart is provided by the 
mitochondrial oxidation of long-chain fatty acids (FAs), with the remainder supplied by 
oxidation of glucose, lactate and ketone bodies [3]. In contrast, fuel preference in fetal hearts 
is determined by the low oxygen environment, in which the oxidation of carbohydrate 
substrate is more energetically efficient per mole of oxygen consumed. Although the 
preferred cardiac metabolic substrate during embryonic development is glucose, lipid 
metabolism is also crucial. RXRα knockout embryos, in which expression of multiple lipid 
metabolic target proteins is downregulated, display malformations and developmental delays 
and die from cardiac failure in utero [4], suggesting a correlation between energy 
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homeostasis and signaling in the fetal heart. Maintaining cardiac lipid homeostasis is crucial 
throughout life, however, and alterations in lipid metabolism in the adult heart may underlie 
the contractile dysfunction associated with senescence. Thus, aging hearts display increased 
levels of saturated FAs in membrane phospholipids, a feature that has been associated with 
decreased membrane fluidity and transport [5]. In addition, reduced mitochondrial content of 
cardiolipin and alterations in cardiolipin FA composition observed in both aging hearts and 
the genetic disorder, Barth syndrome, have been linked to disturbances of the electron 
transport chain assembly and activity, decreased ATP production and increased formation of 
reactive oxygen species (ROS), and defective protein import and mitophagy, which 
ultimately lead to cardiovascular dysfunction [6].
Shortly after birth, the heart undergoes a major switch from the use of glucose and lactate 
towards the use of lipids [7, 8]. This switch in substrate use that occurs as the heart 
transitions to the adult stage is not permanent; healthy adult hearts retain the ability to revert 
to the fetal metabolic program in response to physiological stress [9]. While maintaining 
metabolic flexibility is essential for normal cardiovascular function, a reversion to fetal 
metabolism is also observed in failing hearts [10]. Thus, left ventricular hypertrophy (LVH), 
systemic hypertension, and myocardial ischemia are accompanied by increases in glucose 
use [11]. The loss of cardiac metabolic flexibility in favor of increased FA use is also 
detrimental to heart function, as elevated FA oxidation is observed in metabolic heart disease 
and diabetes [11]. Alterations in substrate use due to mutations in metabolic pathways that 
result in myocardial energy shortage and/or lack of crucial membrane components (e.g., 
cardiolipin deficiency in Barth syndrome [12]) can lead to cardiac hypertrophy and 
dysfunction, whereas an imbalance between FA uptake and oxidation can cause excess lipid 
accumulation, lipotoxicity and associated cardiac pathologies; pertinent studies will be 
summarized in the following sections. Thus, it remains unclear whether the shift in cardiac 
energy substrate is a cause or consequence of pathologic events, and whether this shift is 
beneficial or deleterious to cardiac function. Moreover, our understanding of the 
mechanisms that induce this switch and the regulatory level at which these changes occur 
remains limited. In this review we strive to summarize the abundant literature depicting both 
sides of the coin. The reader will note that we have cited mainly primary references; in 
doing so, we aimed to take a fresh look at the original findings and integrate them with novel 
concepts arising from more recent reports in order to further our understanding of this highly 
debated issue.
Cardiac substrate uptake and metabolism
Cardiac mechanical performance is preferentially sustained by the oxidation of FAs and 
glucose; however, lactate becomes important as a major metabolic substrate during exercise 
[13], and liver-derived ketones may also be used as cardiac fuel during fasting [14]. 
Differences in cardiac substrate use are also species-dependent, with isolated murine hearts 
relying primarily on ketone bodies (34%) and lactate (24%) for energy when exposed to a 
physiological mixture of glucose, glycerol, lactate, pyruvate, acetoacetate, and long-chain 
FAs in the presence of albumin [15]; it is unlikely, however, that acetoacetate and lactate are 
major substrates when VLDL-TAG, the favored suppler of FAs, is present [16, 17]. Thus, the 
heart has been described as a “true omnivore”- that is, functioning optimally when oxidizing 
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different substrates simultaneously [18]. The availability and transport of a substrate into 
cardiomyocytes therefore becomes the rate-limiting step that determines substrate selection, 
and metabolism of the imported substrate will limit the use of other energy sources.
In the immediate postprandial state in rodents fed a low-fat diet, when non-esterified FA 
levels are low and circulating concentrations of glucose and insulin increase, exogenous 
glucose becomes the cardiac fuel of choice [18]. The uptake of extracellular glucose into 
cardiomyocytes occurs along a steep concentration gradient and, due to the hydrophilic 
nature of the substrate, must be facilitated by the transmembrane glucose transporters 
GLUT4 and GLUT1 [19]. These transporters are translocated from intracellular stores to the 
sarcolemma via vesicular trafficking and in response to insulin and contraction [20], stimuli 
which activate independent signaling pathways. Insulin stimulation of cardiac glucose 
uptake occurs via phosphatidylinositol-3 kinase (PI3K) [21, 22], whereas contraction 
increases the intracellular AMP/ATP ratio, which activates AMP-activated kinase (AMPK) 
[23]. GLUT4, the insulin-sensitive transporter, is responsible for the sharp rise in cardiac 
glucose uptake after insulin stimulation or following a sudden increase in heart work [22, 
24]; moreover, AMPK activation can also increase cardiac glucose uptake via GLUT4 
translocation [25]. GLUT1 has generally been regarded as the basal cardiac glucose 
transporter due to its predominantly sarcolemmal location; however, both insulin and 
contraction signaling can trigger the recruitment of additional GLUT1 from intracellular 
pools to the sarcolemma [21, 26, 27], although this recruitment has only a minor effect on 
insulin-stimulated glucose uptake [28]. Increased presence of glucose transporters on the 
plasma membrane also occurs in experimental models of ischemia [29–31], as well as in 
mice with decreased cardiac FA activation caused by cardiomyocyte-specific knockout of 
long-chain acyl-CoA synthetase isoform-1 (Acsl1) [32]. Consequently, each of these models 
exhibits a net increase in the velocity of glucose import and metabolism. Internalized 
glucose is rapidly phosphorylated to glucose-6-phosphate and used primarily for glycolysis, 
although incorporation of glucose into glycogen also occurs, particularly in human 
myocardium [33], in hypertrophied and ischemic hearts [34, 35], under conditions in which 
lactate is the predominant substrate [36, 37], and during fasting [38]. Moreover, and in 
agreement with metabolic substrate preference, glycogen synthesis is high in fetal and 
newborn hearts, in which glycogen occupies 30% of total cardiomyocyte volume [39]. 
Differential cardiac metabolism of carbohydrate may also determine its cellular fate, since 
the heart converts excess extracellular glucose into lactate in the presence of glycogen, 
which, when available, is hydrolyzed to glucosyl moieties that are preferentially oxidized 
[40].
The import and oxidation of FAs becomes critical under fasting conditions when blood 
glucose is low and FAs are released from adipose stores into the circulation. In the fed state, 
however, cardiomyocytes acquire their lipid substrates almost exclusively from the 
lipoprotein lipase (LpL)-mediated hydrolysis of the triacylglycerol (TAG) carried in 
circulating lipoproteins; only a minor contribution comes from non-esterified FAs bound to 
plasma albumin [16, 17]. LpL is located on the luminal membrane of endothelial cells [41–
43], and although different mechanisms of transendothelial FA trafficking have been 
proposed [44–46], the process by which exogenous FAs move across an endothelial cell to 
its basolateral membrane remains unknown (Fig. 1). Also unknown is how FAs are then 
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transported into the subendothelial space in order to reach the cardiomyocyte sarcolemma. 
Despite the ability of amphipathic FAs to partition into biological membranes via passive 
diffusion [47], transport of FAs into cardiomyocytes is thought to occur via a protein-
facilitated process like that of glucose, in which recruitment of protein transporters to the 
sarcolemma plays a major regulatory role [20, 48]. Four proteins have been implicated in the 
uptake of FAs into cardiomyocytes: two plasma membrane proteins, the FA translocase FAT/
CD36 and the FA binding protein (FABPpm) [49], and two very-long-chain acyl-CoA 
synthetases (ACSVL), ACSVL4 and ACSVL2, otherwise known as FA transport proteins 
FATP1 [50] and FATP6 [51], respectively. The presence of the ACSVLs on intracellular 
organelle membranes (ER, mitochondria, and lipid droplets) rather than the plasma 
membrane suggests that they enhance transport by vectorial acylation, i.e. activation, of 
exogenous FAs to acyl-CoAs [52, 53]. In this regard, ACSL1 may also play a major role in 
FA import, given that it accounts for > 90% of total long-chain ACS activity in 
cardiomyocytes [54]. Like glucose transport, FA uptake into cardiomyocytes is stimulated 
by both insulin and contraction. While the effect of insulin on FA uptake is modest (1.5-fold 
for FAs [55] vs 2- to 14-fold for glucose [21, 22, 24, 56, 57]), the resulting increase in FA 
import is significant and CD36-dependent [55]. Contraction induces cardiac FA uptake via 
two related but distinct mechanisms involving the intracellular energy-sensing enzyme 
AMPK, the AMPK-mediated translocation of CD36 to the sarcolemma [58, 59], and the 
AMPK-mediated inhibition of acetyl-CoA carboxylase, which diminishes malonyl-CoA 
levels and thereby de-inhibits carnitine palmitoyltransferase I (CPT-1) [60], the enzyme 
responsible for the first step in mitochondrial FA import. The combined effect of 
contraction-mediated AMPK activation thus leads to an increased uptake of exogenous FAs 
that are preferentially channeled towards mitochondrial β-oxidation. Due to the potential 
toxicity of high intracellular concentrations of free FAs, exogenous FAs are rapidly activated 
upon entry by ACS-mediated esterification to acyl-CoA [61]. This activation step serves to 
effectively trap FAs within cardiomyocytes for their further metabolism, and may provide a 
potential regulatory step in determining their downstream metabolic fate. In line with this 
concept, ACSL1 preferentially targets FAs towards oxidation and away from TAG synthesis 
in heart [54, 62]. CD36 has also been implicated in the compartmentalization of exogenous 
FAs in skeletal myocytes [63]. Overexpression of CD36 in C2C12 myotubes and the 
consequent stimulation of FA transport does not invariably result in TAG accumulation. 
CD36-overexpressing myotubes incubated with exogenous palmitate accumulate TAG, 
whereas exposing the same cells to oleate results in the channeling of incoming FAs to a 
lipase-accessible TAG pool, thereby enhancing TAG turnover and preventing TAG 
accumulation. These data suggest that CD36-mediated transport itself could determine the 
metabolic fate of specific imported FAs, perhaps through the intrinsic properties of the 
distinct FA species that elicit differential interactions with CD36 and/or downstream cellular 
processes. Similarly, inhibiting cardiac LpL activity by either genetic manipulation or the 
use of pharmacological inhibitors results in defective lipid droplet formation even when FA 
uptake is increased [64], indicating that LpL maintains cardiac lipid homeostasis by 
enhancing the cycling of exogenous FAs into intracellular TAG stores. This finding 
challenges long-standing assumptions that cardiomyocytes have little capacity for TAG 
accumulation, or that exogenous non-esterified FAs constitute their major source of 
oxidative substrate. A requirement for FA cycling through an endogenous TAG pool prior to 
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hydrolysis for cardiac β-oxidation is demonstrated by the adipose triglyceride lipase (ATGL) 
deficient model and in isolated hearts. Mice with a global ATGL-deficient background 
exhibit massive cardiac TAG accumulation and develop a lethal cardiomyopathy [65] that 
can be reversed by cardiac-specific overexpression of ATGL [66]. Furthermore, isolated 
wild-type hearts perfused with a physiological mixture of substrates show that 60% of 
exogenous FAs are incorporated into TAG, while 40% of these FAs proceed directly to 
oxidation when mechanical demand is low [15]. This preference for FAs derived from 
intracellular lipid droplets is further enhanced by PPARα-overexpression, suggesting that it 
is mediated by PPARα [66, 67].
In addition to substrate transport and intracellular location of energy stores, cardiac fuel 
selection is regulated by metabolites derived from the degradation of specific substrates. 
Thus, the cardiac metabolism of glucose leads to increased acetyl-CoA production from 
pyruvate and subsequent malonyl-CoA inhibition of CPT-1, ultimately decreasing FA β-
oxidation [60, 68, 69]. Conversely, both the acetyl-CoA and NADH products of FA 
oxidation can allosterically activate pyruvate dehydrogenase kinase (PDK) [70] and directly 
inhibit pyruvate dehydrogenase (PDH) activity [71, 72], thereby reducing PDH flux and 
glucose oxidation. In addition, the Krebs cycle metabolism of the FA-derived acetyl-CoA to 
citrate blocks glycolysis by allosterically inhibiting phosphofructokinase 1 [73]. Thus, FA 
oxidation inhibits glucose oxidation, glycolysis and glucose uptake [26, 74].
Cardiac glucose metabolism: a double-edged sword?
The benefits of increased cardiac glucose use for obesity-related cardiomyopathy or heart 
failure remains a controversial topic [34, 54, 62, 75, 76]. Analysis of several rodent models 
suggests that left ventricular hypertrophy (LVH) precedes the metabolic changes that result 
in increased glucose use and reduced FA oxidation [35, 40, 75]. On the other hand, increased 
reliance on glucose for cardiac energy production has been linked to the development of 
LVH and impaired cardiac function [54, 62, 77–80], suggesting that enhanced glucose use 
precedes the onset of pathology. See Table 1 for a summary of all the models described.
The importance of glucose metabolism in the maintenance of cardiac function under stress 
conditions is underscored by studies of mice with a heart-specific genetic ablation of insulin-
stimulated glucose uptake. Mice deficient in cardiac GLUT4 (G4H−/−) lack insulin-
stimulated glucose uptake, and develop morphological alterations and compensated 
hypertrophy [28]. An observed increase in basal cardiac glucose metabolism is likely 
responsible for the preservation of contractile function in these hearts under normal 
conditions; however, G4H−/− hearts subjected to ischemia-associated stress develop severe 
systolic and diastolic dysfunction due to accelerated ATP depletion [81]. Similarly, mice 
with a cardiac-specific insulin receptor knockout (CIRKO) are defective in heart glucose 
transport and oxidation. CIRKO mice develop cardiac dysfunction during pressure overload-
induced hypertrophy, possibly as a result of insufficient energy production [82]. Thus, an 
adaptive shift in cardiac substrate selection towards the preferential oxidation of 
carbohydrates can be beneficial in an acute setting, and is advantageous in specific models 
of cardiomyopathy. For instance, cardiac-specific overexpression of GLUT1 protects against 
pressure-induced LVH or ischemic stress in the aging heart [83, 84]. Increased glucose 
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uptake and oxidation via cardiac GLUT1 overexpression is also beneficial in the context of 
PPARα deficiency (PPARα−/−) [85]. Metabolic remodeling towards increased glucose use in 
PPARα−/− hearts is sufficient for maintaining energy homeostasis and cardiac function 
under basal conditions, but not when the heart is subjected to an elevated workload; 
however, cardiac-specific GLUT1 overexpression can rescue this defect. Downregulation of 
PPARα and PGC-1α, the master regulators of FA oxidation and mitochondrial biogenesis, is 
widely observed in hypertrophied and failing hearts [86–88]; reductions in the expression of 
CPT-1 and medium-chain acyl-CoA dehydrogenase (MCAD) have also been reported [86, 
88, 89]. The metabolic switch to glucose oxidation in experimental models of hypertrophy is 
therefore presumed to be secondary to the impaired supply of FA. Thus, the improvement in 
cardiac function resulting from increased glucose use in the context of the specific 
cardiomyopathies described could be attributed to enhanced energy production efficiency 
rather than to glucose metabolism per se. However, these beneficial effects appear to be 
short-lived, as demonstrated by studies in hypertrophied myocardium [90] and observations 
in patients with dilated cardiomyopathy [91]. Such studies indicate that, in the long-term, the 
adaptive switch in cardiac metabolism towards increased glycolysis is not sufficient to meet 
the energetic demands of the diseased heart.
In contrast to the models described above in which enhanced glucose use is protective, 
obligate cardiac use of glucose due to genetic modification or forced glucose uptake is 
directly linked to the development of hypertrophy. For example, isolated beating hearts 
perfused with glucose exhibit metabolic changes that precede and mediate the onset of 
decreased cardiac power and output, suggestive of contractile dysfunction [77]. In addition, 
our work in models of altered cardiac FA oxidation resulting from either global or 
cardiomyocyte-specific ACSL1 deficiency suggests that it is the shift to glycolysis that 
promotes a reversion to the fetal metabolic program, the development of cardiac 
hypertrophy, and diastolic dysfunction [32, 54, 62]. Similar effects have been observed in 
hypertensive humans, in which glucose metabolic remodeling precedes the development of 
LVH [80]. Forced glucose uptake is also associated with LVH and cardiac failure in humans 
[92, 93]. This occurs with the administration of the tyrosine kinase inhibitor sunitinib, which 
increases cardiac glucose uptake and use in mice, together with the activation of the fetal 
gene program that is also observed in failing human hearts [94]. Taken as a whole, these 
results are compelling indicators that reliance on glucose is detrimental to cardiac function.
Glucose, mTORC1, and cardiac hypertrophy
A potential cause for the development of LVH and cardiac dysfunction in models of 
increased cardiac glucose use is the activation of mTORC1 (mechanistic target of 
rapamycin, complex 1), a major regulator of cell growth and proliferation [95]. The 
mTORC1 pathway is essential for embryonic heart development and postnatal adaptive 
cardiomyocyte growth and function [96]; however, derangements in mTORC1 signaling 
result in the development of LVH [54, 62, 97, 98]. Activated mTORC1 and subsequent 
phosphorylation of its target, S6 kinase (S6K), is observed in several models of cardiac 
hypertrophy, including spontaneous hypertensive rats [99], thyroid hormone-induced cardiac 
hypertrophy [100], and exercise-induced cardiac hypertrophy [101]. The mTORC1-S6K axis 
is potently activated by glutamine in neonatal cardiomyocytes [102] and by leucine in the 
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adult heart [103]; the link between glucose and mTORC1 activation is less well established. 
In ex vivo working hearts, hemodynamic stress alone can result in increased glucose use and 
mTORC1-responsive cardiac remodeling [104]. Moreover, phosphorylation of glucose and 
the concomitant accumulation of glucose-6-phosphate (G6P) is required and sufficient to 
elicit mTORC1 activation both in vivo and ex vivo [77, 79, 105]. Increased glucose uptake, 
mTORC1 activation, and G6P accumulation are also observed in ACSL1-deficient hearts 
[32, 54, 62], showing that this process occurs in vivo. Mechanical unloading in failing 
human hearts results in decreased G6P levels, further implicating cardiac glucose 
metabolism as a cause of load-induced mTORC1 activation [77].
The regulation of mTORC1 is complex. Among other nodes, mTORC1 activity is inhibited 
by the intracellular energy sensor AMPK [106]. Although AMPK is itself activated by an 
increased AMP/ATP ratio indicative of low cellular energy levels, AMPK levels are reduced 
in isolated rat hearts that have been subjected to an elevated workload, despite marked 
increases in glucose uptake and mTORC1 activation [77]. Similarly, the amount of activated 
AMPK is significantly reduced in Acsl1-deficient ventricles, even though the myocardial 
AMP/ATP ratio remains normal [54]. These studies suggest that an upregulation of glucose 
metabolism is sufficient to maintain energy homeostasis, or alternatively, that AMPK 
activation is reversed by high glucose flux. Although decreases in AMPK phosphorylation 
suggest that AMPK deinhibits mTORC1 in these models, mTORC1 activation may yet be 
unrelated to AMPK activity. In support of this notion, a recent study suggests that AMPK 
does not regulate carbohydrate-mediated S6K phosphorylation, the usual indicator of 
mTORC1 activation [105]. In addition, mTORC1 stimulation of physiological and 
pathological hypertrophy appears to be mediated by eukaryotic translation initiation factor 
4E-BP [107] rather than S6K [108]. Finally, we cannot exclude the possibility that mTORC1 
regulation might be mediated via unknown glucose-responsive effectors. Of note, cardiac 
hypertrophy is not induced by expression of constitutively active mTORC1 or by 
overexpression of wild-type mTORC1 [109, 110]. These findings suggest that mTORC1 
activation alone may not be sufficient to elicit hypertrophy, but that coordinated modulation 
and integration of multiple pathways must exist.
Glucose uptake and N-acetyl-D-glucosamine protein modification
Although the bulk of exogenous glucose is channeled towards oxidation and, to a lesser 
extent, towards glycogen synthesis, other pathways of glucose metabolism have been 
described in cardiomyocytes. The importance of these accessory glycolytic pathways on 
cardiac physiology is beginning to be appreciated, with N-acetyl-D-glucosamine 
modification (O-GlcNAcylation) gaining traction as a potential therapeutic target due to the 
fact that only two enzymes control it: O-GlcNAc transferase (OGT), catalyzing the O-linked 
attachment of N-acetyl-D-glucosamine to serine and threonine residues of nuclear, 
cytoplasmic and mitochondrial proteins; and O-GlcNAcase (OGA), mediating N-acetyl-D-
glucosamine removal [111–113]. Protein glycosylation via this process requires flux through 
multiple metabolic pathways, and, thus, O-GlcNAcylation has been postulated to function as 
a nutrient/metabolic sensor [114]; however, its role in cardiac function has remained 
relatively unknown. The last decade has seen an emergence of studies delineating the link 
between increased cardiac glucose uptake, O-GlcNAcylation and cardiac hypertrophy. 
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Experimental models of pressure-induced hypertrophy indicate that elevated glucose uptake 
results in increased flux through the hexosamine biosynthetic pathway [115]. Consistent 
with this notion, glucose toxicity and insulin resistance correlate with increased cardiac 
protein O-GlcNAcylation [116, 117]. Additionally, O-GlcNAc synthesis is required for the 
transcriptional activation and progression of cardiac hypertrophy [118], and cardiac-specific 
knockout of OGT and the concomitant decrease in O-GlcNAc levels prevent transaortic 
constriction (TAC)-induced hypertrophy [115, 119]. Conversely, protein O-GlcNAcylation is 
cardioprotective in the context of ischemic stress [120]. The paradoxical effects of O-
GlcNAcylation on cardiac hypertrophy and function can be explained by the diversity of 
cellular processes that can be controlled through this pathway. Thus, direct glucose-mediated 
regulation of protein function via O-GlcNAcylation of mitochondrial proteins leads to 
decreased mitochondrial oxygen consumption and ATP production rates [121], thereby 
contributing to cardiac dysfunction. On the other hand, glucose may exert its regulatory 
effects in a more indirect way through the O-linked glycosylation of specific transcription 
factors, eliciting a transcriptional response that leads to a reversion to the fetal metabolic 
program [115]. Finally, glucose-induced O-GlcNAcylation may provide the missing link 
between glucose uptake and AMPK-independent mTORC1 regulation in the development of 
hypertrophy and cardiac dysfunction, perhaps by direct modification and activation of 
mTORC1, or through the inhibition of mTORC1 phosphorylation at specific residues.
Decreased FA oxidation in cardiac function: friend or foe?
Increased cardiac TAG accumulation in human obesity-related cardiomyopathy has been 
associated with structural remodeling such as left ventricular and atrial hypertrophy, and 
functional changes like impaired myocardial contractility [122, 123]. Animal studies have 
recapitulated these findings in models of diet-induced obesity [124], in the genetic obesity 
ob/ob and db/db mouse models [124–127], in mice with cardiac-specific overexpression of 
ACSL1 [128] or FATP1 [129], and in mice with global ATGL deficiency [65]. Thus, 
decreasing the uptake and use of FAs in heart has been proposed as a potential strategy to 
prevent obesity-linked cardiomyopathies. Although decreasing cardiac use of FAs through 
inhibition of CPT-1a [130] or FA oxidation [131] is an interesting approach, data from 
human deficiencies in FA oxidation and animal models with impaired FA oxidative capacity 
have shown that a substantial decrease in FA oxidation results in cardiac hypertrophy [54, 
62, 132–135]. Initial studies of short-term CPT-1 inhibition by oxfenicine treatment in mice 
suggested that this manipulation protects against high fat diet (HFD)-induced insulin 
resistance [136]; however, prolonged HFD feeding causes lipid accumulation and impaired 
insulin signaling [137], effectively reversing the beneficial effects of short-term CPT-1 
inhibition. Partial CPT-1b deletion (CPT1b+/−) results in 80% mortality from congestive 
heart failure after TAC [138], while homozygous CPT-1b knockout mice display cardiac 
hypertrophy and premature mortality under basal conditions [139], illustrating the 
importance of FA oxidation for normal heart function. As described in previous sections, 
abolishing FA oxidation in ACSL1-deficient hearts leads to increased glucose uptake and 
mTORC1-mediated hypertrophy [54, 62]. Manifestations of impaired cardiac FA oxidation 
capacity caused by deficiency of very-long-chain acyl-CoA dehydrogenase (VLCAD) in 
humans include myocardial TAG accumulation and the development of hypertrophic or 
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dilated cardiomyopathy [133, 135]. Rodents, which express both long chain acyl-CoA 
dehydrogenase (LCAD) and VLCAD [140], show no effect of LCAD or VLCAD deficiency 
under normal conditions, despite the presence of cardiac hypertrophy; however 
compensation fails upon fasting, cold exposure, and as a function of age, resulting in energy 
depletion and decreased cardiac performance [141–144]. Decreased FA oxidation capacity 
under conditions of normal or elevated FA availability likely results in the channeling of 
exogenous FA into storage and a concomitant decrease in cardiac performance, arguing 
against therapies that seek to decrease FA oxidation in failing hearts. In addition, the 
resultant increased concentrations of intracellular FA may lead to aberrant cardiac signaling 
and altered acetylation and palmitoylation of proteins. Numerous elegant studies on 
myocardial lipid accumulation, lipotoxicity and cardiac dysfunction have been published; 
for an extended overview on cardiac lipid accumulation and the role of FA in cardiac 
signaling and protein modification, the reader is referred to other articles in this issue. On 
the other hand, HFD interventions are advantageous in preventing and ameliorating cardiac 
dysfunction in several models of heart failure [145–147], and enhanced FA use does not 
necessarily alter cardiac function under basal conditions [148], further challenging the 
notion that enhanced use of FA is detrimental to cardiovascular health.
Perspectives
Decreased oxidation of FA, the preferred energetic substrate in the adult heart, results in 
increased glucose uptake and use. Although this switch in cardiac substrate use has been 
postulated to be beneficial in specific models of cardiomyopathy, increased glucose use may 
also precede the onset of hypertrophy. Suggestions for therapies to treat heart disease have 
focused on compensating the energy deficit in failing hearts by altering cardiac metabolism; 
however, a shift towards glucose use could generate permanent changes in protein function 
and gene expression via mechanisms that have not been fully elucidated. For instance, the 
uncoupling of glycolysis and glucose oxidation in this context allows excess glucose to be 
channeled into alternative glycolytic pathways. Thus, increased glucose flux through the 
hexosamine biosynthetic pathway results in O-GlcNAcylation activation, which can directly 
impact cardiac performance by modifying mitochondrial proteins [121]. More importantly, 
the glycosylation of transcription factors when O-GlcNAc levels are high has been 
postulated to be the central mechanism by which glucose induces a permanent return to the 
fetal metabolic program [94, 115]. Driving enhanced use of glucose also has consequences 
that extend beyond altered myocardial energetics or genetic reprogramming, such as changes 
in membrane composition [149] and mTORC1-mediated inhibition of autophagy [150]. On 
the other hand, decreased cardiac lipid metabolism can cause TAG to accumulate in 
cardiomyocytes and lead to aberrant lipid signaling [66], the production of ROS, ER stress, 
and impaired mitochondrial function. Thus, preserving cardiac metabolic flexibility is 
crucial in order to prevent, and perhaps even reverse, cardiovascular disease. Future efforts 
should therefore be directed towards understanding what controls the availability of cardiac 
substrates, and how this availability can be regulated to balance substrate supply and use 
under specific conditions without altering overall cardiac metabolism.
In this regard, the development of cardiovascular therapies demands a better understanding 
of the role of the endothelium in cardiac substrate selection. Although the facilitated uptake 
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of glucose and FAs at the cardiomyocyte surface has been studied extensively, the precise 
mechanisms that underlie nutrient flow through the subvascular compartment remains 
unknown. Endothelial cells occupy a strategic position between circulating metabolic 
substrates in the blood and cardiomyocytes, raising the intriguing possibility that uptake and 
metabolism within the endothelium may play a major role in determining the rate of 
substrate transport to cardiomyocytes, thereby controlling downstream cardiac substrate 
availability and use. In support of this theory, endothelial cells have been shown to regulate 
glucose uptake by the brain and heart [151]; however, the precise mechanism by which 
glucose is transported through the heart endothelium is yet to be elucidated. In this respect, 
communication between cardiomyocytes and endothelial cells would be essential for 
efficient regulation of substrate delivery. Indeed, a recent study has identified 
cardiomyocyte-derived exosomes loaded with glucose transporters and glycolytic machinery 
components as key in allowing for a rapid response from the endothelium in the coordinated 
regulation of glucose uptake by the heart [152]. Similar mechanisms may govern cardiac FA 
uptake and use. A recent report showed that endothelial cell expression of CD36 and LpL is 
regulated by the Meox2/Tcf15 transcriptional complex, facilitating FA uptake and transport 
across heart endothelial cells, and thereby affecting cardiac contractility [153]. 
Transendothelial FA trafficking may involve CD36, the FA binding proteins FABP4 and 
FABP5 [154], and the membrane-associated proteins FATP3 and FATP4, whose ACS 
activity enhances FA uptake [52, 53]. This raises the question as to whether ACSLs may 
play a similar, and perhaps coordinated, role in FA transport by endothelial cells. Supporting 
this idea, overexpressed FATP1 and ACSL1 interact functionally in yeast [155], and, when 
coexpressed in NIH 3T3 cells, synergistically increase FA import rates [156]. Given the 
distinct tissue expression and cellular locations of the different FATP/ACSVL and ACSL 
isoforms, it has been postulated that these enzymes may coordinately traffic FAs into 
discrete metabolic pools, acting in concert to confer selectivity and specificity to FA use by 
distinct metabolic pathways [157]. We posit that ACSL-mediated activation of FA in 
endothelial cells could perform a dual role: the generation of energy via β-oxidation to 
power FA transport, and the esterification of FA to TAG for storage or vesicular 
transendothelial trafficking to the endothelial cell basolateral membrane for export (Fig. 1). 
Regulation of FA transport through the endothelium via activation by ACSL or FATP/
ACSVL could modulate FA availability for β-oxidation in cardiomyocytes and ultimately 
control cardiac metabolic efficiency. Endothelial cell lipid metabolism therefore warrants 
serious investigation.
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Highlights
• The heart adapts to normal changes in physiology by switching 
metabolic substrates.
• Altered cardiac metabolism has also been identified under pathological 
conditions.
• Increased glucose use may precede the onset of various pathologies.
• Decreased fatty acid oxidation does not ameliorate dysfunction in 
multiple models.
• Alternative strategies investigating transendothelial fuel transport are 
warranted.
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Figure 1. 
Proposed role of endothelial metabolism in regulating cardiac substrate use. The metabolism 
of exogenous FA and glucose within endothelial cells may determine FA availability at the 
cardiomyocyte sarcolemma, thereby regulating cardiac substrate selection and 
cardiomyocyte energy metabolism. Albumin (Alb)-bound fatty acids (FAs) derived from the 
circulation and those hydrolyzed by lipoprotein lipase (LpL) at the cell surface enter 
endothelial cells assisted by the membrane proteins CD36 and FABPpm, a mechanism 
enhanced by acyl-CoA synthetase (ACS)-mediated vectorial acylation. ACS-mediated 
activation of FAs has additional roles: the generation of energy via FA β-oxidation for FA 
transport, or the esterification of FAs to complex lipids for storage and subsequent 
hydrolysis and vesicular or other transendothelial trafficking to the basolateral membrane for 
export. Glucose transport through endothelial cells requires both HIF1α and GLUT1, but the 
underlying mechanism has not been elucidated. Solid lines indicate published data supports 
this mechanism, whereas dashed arrows are used to denote an unknown mechanism.
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